J&J's Q2 Earnings and Key Milestones in Immunology and Oncology

Johnson & Johnson (J&J) recently reported its Q2 earnings, providing insights into the performance of its core divisions, Innovative Medicines and MedTech, following the spin-off of its consumer arm, Kenvue.

July 22, 2024

Small Molecule GLP-1 Overview

Two key GLP-1 updates came out in the last week, both on small molecules: Pfizer's update on danuglipron, and Roche's topline results yesterday on CT-996, which caused shares of competitors to drop sharply - here's the recap:

July 18, 2024

Recap of Recent Radiopharmaceutical Deals

Radiopharmaceuticals are one of the most dynamic segments of BioPharma. Here is a deep dive into some notable deals, and how the biggest companies are approaching the space.

July 15, 2024

The Constant Evolution of Biopharma: A Decade of Transformation

Biopharma companies reinvent themselves every decade, driven by innovation and portfolio changes. Learn about the shifting best-sellers, impacts on sales teams, brand awareness, and strategic decisions in the industry.

July 08, 2024

Top 15 Immunology Drugs by Sales of Q1 '24

Explore the shifting landscape of the immunology market as top-selling drugs face varying futures. Humira's sales slow but stabilize, with AbbVie's Skyrizi and Rinvoq picking up momentum, projecting a combined sales forecast of $27B by 2027. Meanwhile, J&J's Stelara braces for generic competition in early 2025, and Dupixent's sales soar, potentially expanding indications to include COPD.

July 01, 2024

Novartis Navigates Patent Cliff with Robust Pipeline and Strategic Focus

Facing upcoming patent expirations, Novartis is reinforcing its pipeline with promising drugs like Kisqali and Pluvicto. Despite challenges, including complex manufacturing for radioligand therapies, the company's strategic focus and recent divestitures position it well to manage future competition.

June 25, 2024

Top 10 Biopharma Fundraises in April 2024

In April 2024, the top 10 biopharma fundraising rounds totaled more than $2B, yet more than half the haul was from just two companies

May 14, 2024

Which Large Pharma Companies Spend the Most on M&A?

In the past 2 years, 10 of the largest biopharma companies spent a combined $170 BILLION on M&A. But why do some spend much more than others?

May 07, 2024

Top 15 Biopharma Companies by Oncology Sales

Oncology is the largest single therapeutic area within the global biopharma market, worth over $200B. While a lot of analysis is focused on sales of individual drugs, it is also helpful to take a look at oncology sales by company overall to help paint a fuller picture.

May 07, 2024

The 15 Biggest Biotech and Pharma Fundraisings in Q1 2024

The 15 largest biotech fundraisings picked up ~$2.8B in Q1, showing that capital markets are seeing improved sentiment after 2 years of difficulty.

May 03, 2024